A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis

Rui Chen; Wantao Wu; Wantao Wu; Wantao Wu; Si-Yu Chen; Si-Yu Chen; Si-Yu Chen; Zheng-Zheng Liu; Zheng-Zheng Liu; Zhi-Peng Wen; Jing Yu; Jing Yu; Long-Bo Zhang; Long-Bo Zhang; Zaoqu Liu; Jian Zhang; Peng Luo; Wen-Jing Zeng; Wen-Jing Zeng; Quan Cheng; Quan Cheng

doi:10.3389/fimmu.2022.831542

Frontiers in Immunology (Aug 2022)

A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis

Rui Chen,
Wantao Wu,
Wantao Wu,
Wantao Wu,
Si-Yu Chen,
Si-Yu Chen,
Si-Yu Chen,
Zheng-Zheng Liu,
Zheng-Zheng Liu,
Zhi-Peng Wen,
Jing Yu,
Jing Yu,
Long-Bo Zhang,
Long-Bo Zhang,
Zaoqu Liu,
Jian Zhang,
Peng Luo,
Wen-Jing Zeng,
Wen-Jing Zeng,
Quan Cheng,
Quan Cheng

Affiliations

Rui Chen: Department of Neurosurgery, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China
Wantao Wu: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
Wantao Wu: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Wantao Wu: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Si-Yu Chen: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
Si-Yu Chen: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Si-Yu Chen: Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
Zheng-Zheng Liu: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Zheng-Zheng Liu: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Zhi-Peng Wen: Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
Jing Yu: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Jing Yu: Department of Pharmacy, The Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, China
Long-Bo Zhang: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Long-Bo Zhang: Department of Neurosurgery, and Department of Cellular & Molecular Physiology, Yale University School of Medicine, New Haven, CT, United States
Zaoqu Liu: Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Jian Zhang: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China
Peng Luo: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China
Wen-Jing Zeng: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Wen-Jing Zeng: Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
Quan Cheng: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
Quan Cheng: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China

DOI: https://doi.org/10.3389/fimmu.2022.831542
Journal volume & issue: Vol. 13

Abstract

Read online

BackgroundCLEC5A is a member of the C-type lectin superfamily. It can activate macrophages and lead to a series of immune-inflammation reactions. Previous studies reveal the role of CLEC5A in infection and inflammation diseases.MethodWe acquire and analyze data from The Cancer Genome Atlas (TCGA) database, Genotype-Tissue Expression (GTEx) database, and other comprehensive databases via GSCALite, cBioPortal, and TIMER 2.0 platforms or software. Single-cell sequencing analysis was performed for quantifying the tumor microenvironment of several types of cancers.ResultsCLEC5A is differentially expressed in a few cancer types, of which overexpression accompanies low overall survival of patients. DNA methylation mainly negatively correlates with CLEC5A expression. Moreover, CLEC5A is positively related to immune infiltration, including macrophages, cancer-associated fibroblasts (CAFs), and regulatory T cells (Tregs). Immune checkpoint genes are significantly associated with CLEC5A expression in diverse cancers. In addition, CLEC5A expression correlates with mismatch repair (MMR) in several cancers. Tumor mutation burden (TMB), microsatellite instability (MSI), and neoantigens show a positive association with CLEC5A expression in several cancers. Furthermore, CLEC5A in cancer correlates with signal transduction, the immune system, EMT, and apoptosis process. The drug sensitivity analysis screens out potential therapeutic agents associated with CLEC5A expression, including FR-180204, Tivozanib, OSI-930, Linifanib, AC220, VNLG/124, Bexarotene, omacetaxine mepesuccinate, narciclasine, leptomycin B, PHA-793887, LRRK2-IN-1, and CR-1-31B.ConclusionCLEC5A overexpresses in multiple cancers in contrast to normal tissues, and high CLEC5A expression predicts poor prognosis of patients and immune infiltration. CLEC5A is a potential prognostic biomarker of diverse cancers and a target for anti-tumor therapy.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords